According to recent news China is reporting that it intends to accelerate the approval process for new medication by accepting the data from international clinical trials. This is obviously great news for many patients in need of new generation drugs such as immunotherapy.
By adopting this more open approach, the world’s second-largest drug market is providing exciting news to the international Pharma industry. In the long run, however, this move will reassure the steady drive of many R&D departments around the world and be a springboard for China to become a serious player in the development of new medication.